Beasley Allen has one of the largest and most technologically advanced Mass Torts practices in the country. The Mass Torts division represents numerous people in claims against companies that manufacture and/or market defective pharmaceuticals and/or medical devices. The resources devoted to this division allow the firm to competently and conscientiously handle any group of cases, no matter how large, along with particular catastrophic injury cases.
Our firm was recently involved in one of the greatest victories in Mass Torts history, against drug manufacturer Merck regarding the drug Vioxx. After more than five years of hard-fought and difficult litigation, Merck agreed to pay $4.85 billion, the largest pharmaceutical settlement in U.S. history, to resolve certain Vioxx-related claims involving plaintiffs who suffered a heart attack, including sudden cardiac death, or a stroke.
Makers of the blood thinner Xarelto overstated the effectiveness of the drug, failed to fully research the medication to better understand the risks, and knowingly concealed problems associated with the drug, according to a lawsuit filed by a California man. Kenneth Niemeier claims he suffered injuries after being treated with Xarelto, resulting in physical pain, mental anguish, diminished enjoyment of life, loss of earnings and medical expenses. His lawsuit names Janssen Research & Development, a subsidiary of Johnson & Johnson, and Bayer Healthcare Pharmaceuticals, alleging product liability. Xarelto is an anticoagulant used to prevent or treat blood clots in patients ... Read More
Researchers have found a way to coax pancreatic cancer cells to revert back to normal cells by adding a protein that binds to specific DNA sequences and controls the genes involved in the growth and differentiation of the cells. The finding offers a glimmer of hope to people with pancreatic cancer, a disease that claims about 40,000 lives a year. “For the first time, we have shown that overexpression of a single gene can reduce the tumor-promoting potential of pancreatic adenocarcinoma cells and reprogram them toward their original cell type. Thus, pancreatic cancer cells retain a genetic memory which we ... Read More
Regulators of European medical devices have released a fact sheet detailing the pros, cons and potential health risks for patients who choose to receive so-called metal-on-metal hip implants. The European Commission’s Scientific Committee on Emerging and Newly Identified Health Risks compiled the fact sheet to address concerns about premature failures and injuries caused by the all-metal devices. Traditional hip replacement systems are made of ceramic or plastic parts, and can last up to 20 years or longer. But in recent years manufacturers have produced hip implants made with metal parts under the guise that all-metal hip implants would be more ... Read More
Olympus Corp. warned European hospitals about the risk of antibiotic-resistant bacterial infections associated with its gastrointestinal duodenoscopes two years before the deadly superbug outbreaks at UCLA Ronald Reagan Medical Center and Cedars-Sinai Medical Center in Los Angeles, the Los Angeles Times reported. While the first of two European alerts came in January 2013, the U.S. never received a warning from Olympus. It was not until the day after the Los Angeles Times reported on Feb. 18 that 179 patients may have been exposed to the deadly carbapenem-resistant Enterobacteriaceae (CRE), a virulent type of bacteria that resists antibiotics and can kill ... Read More
Merck & Co.’s cancer drug Keytruda (pembrolizumab) was more successful at improving survival odds of patients with melanoma than the Bristol-Myers Squibb Co.’s Yervoy (lpilimumab) in a clinical trial that pitted the two drugs against each other. Keytruda and Yervoy are immunotherapies that work differently to toughen the body’s immune system to destroy cancerous tumors. Yervoy has emerged as the first-line treatment for advanced melanoma since its approval in 2011. Keytruda was approved in 2014 to treat melanoma in patients whose disease progressed after treatment with Yervoy. Yervoy was the first medication approved for advanced melanoma that studies showed could ... Read More
Unapproved prescription drugs valued at more than $1.5 million made by Sonar Products and marketed by Stratus Pharmaceuticals, were seized by U.S. Marshals. The Food and Drug Administartion and the U.S. Attorney for the Southern District of Florida ordered the seizure of the products because they may not be safe or effective. The products seized include a solution used to treat excessive sweating; an antibiotic cleanser to treat skin conditions including acne, rosacea and seborrhea; a topical ointment used to treat wounds; a topical cream and gel to treat psoriasis, eczema and other skin conditions; and analgesic ear drops to ... Read More
The black box warning on the menopausal cream Estrasorb has been updated to include warnings for endometrial cancer, cardiovascular disorders, breast cancer and probable dementia. Estrasorb is a topical cream that is used to treat moderate to severe hot flashes in postmenopausal women. It contains the hormone estradiol, which is the predominant female hormone. As women age, levels of estrogen drop, which can lead to symptoms including hot flashes and vaginal dryness. The updated boxed warning for Estrasorb informs users of an increased risk of endometrial – or uterine – cancer in women who still have their uteruses. The label ... Read More
The risk of developing type 2 diabetes among people who use cholesterol-lowering statin therapy is greater than previously thought, a new study published in the journal Diabetologia, has found. For years, researchers have known that statins, such as the widely prescribed Lipitor, can increase blood sugar levels, a precursor to type 2 diabetes. In 2013, the British Medical Journal reported that statin therapy increased a person’s risk of developing type 2 diabetes by 22 percent. The news sent shockwaves around the world, as statins are the most prescribed drug in the world, and type 2 diabetes is growing worldwide in epidemic proportions. ... Read More
Several lots of the over-the-counter cold medicine Mucinex are being recalled by the manufacturer because the packages may be mislabeled with incorrect drug facts. This could prevent consumers from knowing the risks or side effects associated with certain ingredients which could lead to health complications requiring urgent medical intervention, particular for people with liver impairment. The recall includes several lots of liquid Mucinex Fast-MAX Night Time Cold & Flu; Mucinex Fast-MAX Cold & Sinus; Mucinex Fast-MAX Severe Congestion & Cough; and Mucinex Fast-MAX Cold, Flu & Sore Throat. A full list of lot numbers can be found here. The medicines ... Read More
The Food and Drug Administration (FDA) is alerting doctor’s offices and medical clinics across the country to look for shipments of possible counterfeit Botox injections made by an unlicensed supplier that is not authorized to ship or distribute the drug in the United States. Packages of the counterfeit Botox are strikingly similar to the FDA-approved packages of Botox, which is made by Allergan. But the fake Botox can be discerned from the approved drug in a few ways. For example, the active ingredient on the outer carton and vial of the authentic Botox is listed as “OnabotulinumtoxinA.” However, the outer ... Read More